PPARs, metabolic disease and atherosclerosis

被引：91

作者：

Fruchart, JC

Staels, B

Duriez, P

机构：

[1] Univ Lille 2, F-59800 Lille, France

[2] Inst Pasteur, INSERM, U545, Dept Atherosclerose, F-59019 Lille, France

[3] Inst Pasteur, INSERM, U545,Fac Pharm, Unite Rech Lipoprot & Atherosclerose, F-59019 Lille, France

来源：

PHARMACOLOGICAL RESEARCH | 2001年 / 44卷 / 05期

关键词：

PPAR-alpha; lipoprotein metabolism; atherosclerosis; metabolic disease;

D O I：

10.1006/phrs.2001.0871

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PPAR-alpha belongs to the family of nuclear receptors. Activated PPAR-alpha stimulates the expression of genes involved in fatty acid and lipoprotein metabolism. PPAR-alpha activators, such as the normolipidaemic fibric acids, decrease triglyceride concentrations by increasing the Zn expression of lipoprotein lipase and decreasing apo C-III concentration. Furthermore, they increase HDL-cholesterol by increasing the expression of apo A-I and apo A-II. PPAR-alpha activation by fibric acids improves insulin sensibility, and decreases thrombosis and vascular inflammation, PPAR-alpha activators (gemfibrozil) decrease the risk of coronary heart disease in patients with normal LDL-cholesterol and low HDL-cholesterol (VA-HIT) and they slow the progression of premature coronary atherosclerosis (BECAIT) (bezafibrate), particularly in patients with type 2 diabetes (DAIS) (fenofibrate). (C) 2001 Academic Press.

引用

页码：345 / 352

页数：8

共 65 条

[1]

AaltoSetala K, 1996, J LIPID RES, V37, P1802

[2] MECHANISM OF HYPERTRIGLYCERIDEMIA IN HUMAN APOLIPOPROTEIN-(APO)-CIII TRANSGENIC MICE - DIMINISHED VERY LOW-DENSITY-LIPOPROTEIN FRACTIONAL CATABOLIC RATE ASSOCIATED WITH INCREASED APO-CIII AND REDUCED APO-E ON THE PARTICLES [J].

AALTOSETALA, K ;

FISHER, EA ;

CHEN, XL ;

CHAJEKSHAUL, T ;

HAYEK, T ;

ZECHNER, R ;

WALSH, A ;

RAMAKRISHNAN, R ;

GINSBERG, HN ;

BRESLOW, JL .

JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (05) :1889-1900

[3] A MULTICENTER COMPARISON OF THE EFFECTS OF SIMVASTATIN AND FENOFIBRATE THERAPY IN SEVERE PRIMARY HYPERCHOLESTEROLEMIA, WITH PARTICULAR EMPHASIS ON LIPOPROTEINS DEFINED BY THEIR APOLIPOPROTEIN COMPOSITION [J].

BARD, JM ;

PARRA, HJ ;

CAMARE, R ;

LUC, G ;

ZIEGLER, O ;

DACHET, C ;

BRUCKERT, E ;

DOUSTEBLAZY, P ;

DROUIN, P ;

JACOTOT, B ;

DEGENNES, JL ;

KELLER, U ;

FRUCHART, JC .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (05) :498-503

[4] Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice [J].

Berthou, L ;

Duverger, N ;

Emmanuel, F ;

Langouet, S ;

Auwerx, J ;

Guillouzo, A ;

Fruchart, JC ;

Rubin, E ;

Denefle, P ;

Staels, B ;

Branellec, D .

JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) :2408-2416

[5] Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].

Braissant, O ;

Foufelle, F ;

Scotto, C ;

Dauca, M ;

Wahli, W .

ENDOCRINOLOGY, 1996, 137 (01) :354-366

[6] FENOFIBRATE AND LDL METABOLIC HETEROGENEITY IN HYPERCHOLESTEROLEMIA [J].

CASLAKE, MJ ;

PACKARD, CJ ;

GAW, A ;

MURRAY, E ;

GRIFFIN, BA ;

VALLANCE, BD ;

SHEPHERD, J .

ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (05) :702-711

[7]

CATTIN L, 1990, CLIN THER, V12, P482

[8] CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors [J].

Chinetti, G ;

Gbaguidi, FG ;

Griglio, S ;

Mallat, Z ;

Antonucci, M ;

Poulain, P ;

Chapman, J ;

Fruchart, JC ;

Tedgui, A ;

Najib-Fruchart, J ;

Staels, B .

CIRCULATION, 2000, 101 (20) :2411-2417

[9] Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages [J].

Chinetti, G ;

Griglio, S ;

Antonucci, M ;

Torra, IP ;

Delerive, P ;

Majd, Z ;

Fruchart, JC ;

Chapman, J ;

Najib, J ;

Staels, B .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (40) :25573-25580

[10] PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway [J].

Chinetti, G ;

Lestavel, S ;

Bocher, V ;

Remaley, AT ;

Neve, B ;

Torra, IP ;

Teissier, E ;

Minnich, A ;

Jaye, M ;

Duverger, N ;

Brewer, HB ;

Fruchart, JC ;

Clavey, V ;

Staels, B .

NATURE MEDICINE, 2001, 7 (01) :53-58

← 1 2 3 4 5 6 7 →